The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
- Author:
Sunil AMIN
1
;
Paolo BOFFETTA
;
Aimee L LUCAS
Author Information
- Publication Type:Review
- Keywords: Pancreas; Malignancy; Adenocarcinoma; Epidemiology; Aspirin; Metformin; Statins; Bisphosphonates; Beta-blockers; Dipeptidyl-peptidase 4 inhibitors
- MeSH: Adenocarcinoma; Aspirin; Dipeptidyl-Peptidase IV Inhibitors; Diphosphonates; Epidemiology; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Pancreas; Pancreatic Neoplasms*
- From:Gut and Liver 2016;10(5):665-671
- CountryRepublic of Korea
- Language:English
- Abstract: Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.
